|Year : 2008 | Volume
| Issue : 6 | Page : 282
Department of Pharmacology, RNT Medical College, Udaipur-313 001, India
Department of Pharmacology, RNT Medical College, Udaipur-313 001
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Khilnani G. Authors' reply. Indian J Pharmacol 2008;40:282
I thank you for your keen interest and comments  on the correspondence, 'The concept of personal drugs in the undergraduate pharmacology practical curriculum.'  I have to submit the following in reply:
The usual recommended dose of tinidazole is 2 g/day for three days. The dose (1 g) given in the above letter was inadvertently typed and should be read as 2 g/day. However, the cost factor and the suitability remain the same. Metronidazole is usually given as 800 mg TDS for 5-10 days. Both metronidazole and tinidazole are equally effective, but tinidazole is given for a shorter course and is better tolerated. 
With regard to matter of the inadequate price search, kindly note that drug prices vary from time to time, but the relatively lower cost of tinidazole treatment should not be undermined. If one chooses the least expensive brands for tinidazole and metronidazole,  the cost for one course would be as shown in [Table 1].
It is clear that the cost of tinidazole is somewhat lower than that of metronidazole and it is more convenient to take twice a day for three days only. It is, therefore, reiterated that using the criteria of efficacy, safety, suitability, and affordability, I would select tinidazole as my "P" drug.
| » References|| |
|1.||Parmar DM, Jadav SP. The concept of personal drugs in the undergraduate pharmacology practical curriculum. Indian J Pharmacol 2008;40:281. |
|2.||Khilnani G. The concept of personal drugs in the undergraduate pharmacology practical curriculum. Indian J Pharmacol 2008;40:131-2. |
|3.||Goldsmith RS. Infectious diseases: Protozoal and Helminthic (Chapter 35). In: McPhee SJ, Papadakis MA, editors. Current Medical Diagnosis and Treatment, 46th ed. McGrawHill: New Delhi; 2007. p. 1502. |
|4.||Malik S, editor. Indian Drug Review Triple -I. Bangalore, India: CMP Medica India Pvt Ltd; July-Aug, 2008. p. 286, 334. |